Published: 4 December 2025
Publications
Quarterly summary of recent safety communications
Published: 4 December 2025
Prescriber Update 46(4): 60
December 2025
The table below is a summary of recent safety communications for healthcare professionals and consumers. Click on a specific topic to go to the communication.
|
Date
|
Communication
|
Topic
|
|
11/11/2025
|
Monitoring
|
Further Update - Estradot (estradiol) transdermal patches: reports of quality and efficacy
|
|
04/11/2025
|
Monitoring
|
Update - Estradot (estradiol) transdermal patches: reports of quality and efficacy
|
|
22/10/2025
|
Dear Healthcare Professional Letter
|
Recent complaints for Estradot transdermal patches (25, 50, 75 and 100 mcg/24 hrs) (PDF, 3 pages, 451 KB)
|
|
22/10/2025
|
Monitoring
|
Estradot (estradiol) transdermal patches: reports of quality and efficacy
|
|
13/10/2025
|
Dear Healthcare Professional Letter
|
Paxlovid (nirmatrelvir/ritonavir) treatment in patients with severe renal impairment (PDF, 5 pages, 322 KB)
|
|
26/09/2025
|
News article
|
Ministry of Health: Paracetamol use in pregnancy
|
|
24/09/2025
|
Dear Healthcare Professional Letter
|
Risperdal: Discontinuation of Risperdal (risperidone) tablets across all strengths as of 15 December 2025 (PDF, 3 pages, 213 KB)
|
|
23/09/2025
|
Alert
|
Topiramate: New measures and advice to prevent exposure during pregnancy
|
|
22/09/2025
|
Dear Healthcare Professional Letter
|
Ribomustin: Discontinuation of Ribomustin (bendamustine hydrochloride) 25mg & 100mg powder for infusion as of 30 November 2025 (PDF, 2 pages, 216 KB)
|
|
17/09/2025
|
Dear Healthcare Professional Letter
|
Epilim: Updated safety information for valproate: Risk in pregnancy and women of childbearing potential – lower birth weight following in utero exposure to valproate (PDF, 2 pages, 167 KB)
|
|
15/09/2025
|
Dear Healthcare Professional Letter
|
Lenalidomide Viatris (lenalidomide) capsules: NZ-specific cartons (PDF, 2 pages, 379 KB)
|
|
12/09/2025
|
Dear Healthcare Professional Letter
|
Polivy: Infusion site extravasation is a new identified risk for Polivy (polatuzumab vedotin) (PDF, 3 pages, 169 KB)
|
|
08/09/2025
|
Dear Healthcare Professional Letter
|
Tegretol (carbamazepine) liquid: limitation of use in neonates (PDF, 1 page, 156 KB)
|
Note that sponsors write Dear Healthcare Professional Letters and distribute them to relevant healthcare professionals. Medsafe publishes copies of these letters on the Medsafe website.
